Full Text View
Tabular View
No Study Results Posted
Related Studies
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
This study has been completed.
Study NCT00004832   Information provided by FDA Office of Orphan Products Development
First Received: February 24, 2000   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lambert-Eaton Myasthenic Syndrome
Additional conditions recognized in this trial
Syndrome
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Disease
Immune System Diseases
Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms
Neurodegenerative Diseases
Neuromuscular Diseases
Neuromuscular Junction Diseases
Paraneoplastic Syndromes
Paraneoplastic Syndromes, Nervous System
Pathologic Processes
Interventions listed in this trial
3,4-diaminopyridine
Additional drug interventions recognized in this trial
4-Aminopyridine
More general drug interventions related to this trial
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Potassium Channel Blockers
Therapeutic Uses
Sponsors listed in this trial
FDA Office of Orphan Products Development
Duke University


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services